Tempest Therapeutics (NASDAQ:TPST) Releases Quarterly Earnings Results

Tempest Therapeutics (NASDAQ:TPST) released its quarterly earnings data on Friday. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.11, Zacks reports.

Tempest Therapeutics Stock Performance

Shares of NASDAQ TPST traded down $0.00 during trading hours on Friday, reaching $0.38. 153,029 shares of the stock were exchanged, compared to its average volume of 881,778. The firm has a market capitalization of $7.64 million, a price-to-earnings ratio of -0.09 and a beta of -1.54. Tempest Therapeutics has a 52 week low of $0.34 and a 52 week high of $9.75. The stock’s fifty day simple moving average is $0.70 and its 200 day simple moving average is $1.40.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Tempest Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempest Therapeutics in a research note on Friday, October 9th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce”.

About Tempest Therapeutics

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s approach is designed to address both tumor cells and the immune environment surrounding them, with the goal of stimulating antitumor immune responses and improving the effectiveness of cancer treatment. Tempest’s pipeline includes TPST-1120, an orally administered, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα). The company has evaluated TPST-1120 in clinical studies involving advanced solid tumors, including hepatocellular carcinoma, and has investigated its use in combination with other cancer therapies.